Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

Nicola Colclough, Kan Chen, Peter Johnström, +32

Clinical Cancer Research

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6

William McCoull, Tony Cheung, Erica Anderson, +34

ACS Chemical Biology

Hematological MalignancyLymphoid NeoplasiaB-cell Lymphoma 6MedicineMalignant Blood Disorder +12

Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors

William McCoull, Roman Abrams, Erica Anderson, +31

Journal of Medicinal Chemistry

Identification, Optimization, and Pharmacology of Acylurea GHS-R1a Inverse Agonists

William McCoull, Peter Barton, Alastair Brown, +19

Journal of Medicinal Chemistry

NutritionReduced Food IntakeFood IntakePharmacotherapyGastrointestinal Peptide Hormone +16

Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy

William McCoull, Andrew Bailey, Peter Barton, +18

Journal of Medicinal Chemistry

Molecular PharmacologyGpr120 AgonistsGpr120 PotencyMedicineFunctional Selectivity +10

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance

M. Raymond V. Finlay, Peter Barton, Sue Bickerton, +29

Journal of Medicinal Chemistry

Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase

Sharan K. Bagal, Clare Gregson, Daniel H. O’Donovan, +21

Journal of Medicinal Chemistry

Chemoprevention StrategyEpigenetic ChangeEfficacious InhibitorsMolecular BiologyChemical Biology +20

Identification of pyrazolo-pyrimidinones as GHS-R1a antagonists and inverse agonists for the treatment of obesity

William McCoull, Peter Barton, Anders Broo, +21

MedChemComm

Inverse AgonistsImmunologyFood IntakePharmacotherapyGastrointestinal Peptide Hormone +18

Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs

Nicola Colclough, Pete G. Ballard, Peter Barton, +12

European Journal of Cancer

Neuro-oncologyBlood Brain BarrierBlood–brain BarrierVascular BiologyBrain Injury +9

Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase

Daniel H. O’Donovan, Clare Gregson, Martin J. Packer, +15

Bioorganic & Medicinal Chemistry Letters

BiochemistryFree Energy PerturbationNatural SciencesCoordination ComplexMolecular Biology +3